FindTrial
Sign In

Hemofiltration for prevention of contrast-induced nephropathy after PCI in patients with coronary heart disease complicated with moderate renal impairment:a randomized, controlled, single-center study

Hemofiltration for prevention of contrast-induced nephropathy after PCI in patients with coronary heart disease complicated with moderate renal impairment:a randomized, controlled, single-center study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057255
Enrollment
Unknown
Registered
2022-03-05
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease complicated with moderate renal impairment

Interventions

Experimental group:Hemofiltration + hydration
Control Group:Hydration

Sponsors

Nanjing Drum Tower Hospital, Medical School of Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Older than 18 years; 2. Indications for coronary angiography; 3. Preoperative renal function staging was calculated as 15-60 mL /min/1.73m2 according to creatinineclearance (CrCl); 4. Indications of PCI after coronary angiography; 5. There are indications for coronary artery bypass grafting.

Exclusion criteria

Exclusion criteria: 1. Acute renal insufficiency; 2. Patients dependent on hemodialysis or peritoneal dialysis; 3. Acute ST-segment elevation myocardial infarction requires emergency PCI; 4. EF value of left ventricular systolic function is less than 40%; 5. Patients with NewYorkHeartAssociation (NYHA) heart function grading III-IV or Killip grading III-IV; 6. Patients are using diuretics; 7. Co-infection; 8. Recent use of non-steroidal anti-inflammatory drugs; 9. After kidney transplantation; 10. Used contrast agent within 3 weeks before admission; 11. Deep vein thrombosis of lower limbs; 12. Those who are receiving anticoagulation treatment; 13. Abnormal coagulation system; 14. Platelet is lower than the lower limit of normal value; 15. Patients who are pregnant, breast-feeding or planning to become pregnant; 16. There are contraindications to coronary intervention therapy; 17. The subject is participating in clinical trials of other drugs or medical devices; 18. Moderate to severe cognitive impairment and no long-term fixed custodian; 19. Patients considered unsuitable for the study by the investigator.

Design outcomes

Primary

MeasureTime frame
Serum creatinine;—

Secondary

MeasureTime frame
Routine blood;Serum troponin T;Urinary N-acetyl ß-D glucosaminidase;—

Countries

China

Contacts

Public ContactWang Kun

Nanjing Drum Tower Hospital, Medical School of Nanjing University

kingwang726@163.com+86 13813866868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026